

Ventrio™ ST Hernia Patch

Featuring Sepra[™] Technology




The Ventrio[™] ST Hernia Patch featuring Sepra[™] Technology

An extensively studied barrier with more than 10 publications and used clinically since 2007.

Unique hydrogel barrier swells to minimize tissue attachment to the visceral side of the mesh.¹

Bioresorbable PGA fibers reinforce the integrity of the hydrogel barrier by binding it to the polypropylene mesh.

The hydrogel barrier resorbs within 30 days providing visceral protection during the critical healing period.¹



It begins with a hydrogel barrier. It ends with a strong, long-term repair.



Easy

- Provides the benefits of a laparoscopic repair through the ease of an open anterior incision.
- SorbaFlex™ Memory Technology allows the patch to "spring open," lay flat to maintain shape and then fully absorbs over time.¹
- Simplifies placement and positioning of the patch throughout the ventral hernia repair.



Efficient

- Unique pocket aids in the proper placement and positioning of the patch.
- Designed to facilitate the use of mechanical fixation devices and/or sutures.
- Available in a variety of shapes and sizes to accommodate defect sizes and locations




Proven


- Hydrogel barrier is based on Sepra Technology.
- Uncoated monofilament polypropylene mesh allows for complete tissue ingrowth leading to a strong repair.
- Materials have been used in general surgery for years with demonstrated clinical success.²

Easy

The Ventrio $^{\text{TM}}$ ST Hernia Patch's unique design provides the benefit of laparoscopic repair through the ease of a smaller incision.







Intraabdominal placement through a small open incision³

- No preperitoneal lateral dissection may reduce surgical time and lead to quick patient recovery.
- Minimized dissection may reduce the chance of infection and seroma as well as the need for drains.
- The unique SorbaFlex[™] Memory Technology permits rolling of the patch for easy insertion, allowing the patch to "spring open," lay flat to maintain shape and then fully absorbs over time.

Established Technique Supported by Published Clinical Data³


- The design of the Ventrio[™] ST Hernia Patch allows the use of the familiar Ventrio[™] Hernia Patch technique for open ventral hernia repair.
- Technique is peer reviewed and supported by published clinical data.²




Efficient

The unique positioning pocket aids in proper placement and positioning, while also allowing the use of mechanical fixation, for a quick efficient repair. The monofilament polypropylene results in strong tissue incorporation within a short period of time, providing the long-term strength of the repair.









Variety of sizes available

Ventrio[™] ST Hernia Patch is available in a variety of shapes and sizes to meet your surgical needs dependent on defect size and location. A unique mid-line oval shaped patch designed for multiple defects is also available.

Mechanical fixation

The Ventrio™ ST Hernia Patch is compatible in both open and laparoscopic ventral procedures with the OptiFix™ Absorbable Fixation System and the CapSure™ Permanent Fixation System.



Proven

The Ventrio[™] ST Hernia Patch combines materials used in general surgery for many years to deliver proven benefits to you and your patients.

Uncoated monofilament polypropylene mesh ——

- Over 40 years of proven results in hernia repair.
- Allows a fast fibrotic response for a strong repair.
- Provides a long-term repair with minimized recurrence.



Open pore mesh design. 35x magnification.


Sepramesh™ IP Composite

- Hydrogel barrier is based on the Sepra[™] technology which has more than 10 publications and used clinically since 2007.
- Unique hydrogel barrier swells to minimize tissue attachment to the visceral side of the mesh.¹
- Resorbs within 30 days providing visceral protection during the critical healing process.
- Bioresorbable PGA fibers reinforce the integrity of the hydrogel barrier by binding it to the polypropylene mesh.

SorbαFlex™ Memory Technology

- Polydioxanone (PDO) monofilament is commonly used in other well-known surgical products (e.g. suture).
- Unique in its flexibility and tensile strength, it facilitates patch insertion and proper placement.
- Absorption via hydrolysis is essentially complete in 24–32 weeks.¹

Cross section view



PGA Bioresorbable coating

Gross explants









Histology









These images are from a porcine study using the Ventrio™ Hernia Patch which contains the same SorbaFlex™ Memory Technology.¹

Clinical success


Ventrio[™] ST Hernia Patch preclinical results⁴



Initial implant



2 weeks



Strength of tissue ingrowth in a preclinical study⁵

 $Logarithmic \ regression \ curve \ of \ mean \ force \ of \ lap-shear \ strength \ as \ a \ function \ of \ time. \ \textbf{74\% \ of the 12-week}$ $\textbf{strength \ is \ achieved \ by \ 2 \ weeks \ postoperatively.}^{5,6}$

Sepramesh[™] IP Composite – a preclinical study⁷

120 day comparative analysis of adhesion grade and quantity, mesh contraction, and tissue response to a novel omega-3 fatty acid bioresorbable barrier macroporous mesh after intraperitoneal placement.

Pierce, R., Perrone, J., Abdelrahman, N., Sexton, J., Walcutt, J., Frisella, M., Matthews, B. Surgical Innovation. 2009 Mar; 16(1): 46-54.8

| Mesh | N | Adhesion grade (1–4) | Adhesion coverage (%) | Mesh contraction (%) |
|---|----|----------------------------|-----------------------------|----------------------------|
| Sepramesh™ IP Composite | 6 | 1.0 ± 0.0 | 0.0 ± 0.0 | 6.4 ± 8.4 |
| Lightweight polypropylene flat mesh | 12 | 1.7 ± 1.1 | 10.7 ± 19.8 | 9.1 ± 8.3 |
| Polypropylene with Omega 3 coating | 6 | 1.2 ± 0.4 | 3.0 ± 7.3 | 3.3 ± 2.1 |
| Composix | 10 | 1.9 ± 1.2 | 24.8 ± 37.0 | 7.2 ± 7.1 |
| Dual-surface polytetrafluoroethylene mesh(ePTFE) material | 10 | 1.3 ± 0.9 | 1.4 ± 4.4 | 39.0 ± 6.0 |
| Monofilament Polyester Mesh® | 6 | 1.2 ± 0.4 | 0.8 ± 2.0 | 14.7 ± 5.0 |
| Polypropylene with ORC & polydioxanone polymer | 6 | 2.8 ± 1.0 | 28.8 ± 16.1 | 29.7 ± 12.5 |

Ordering information

| Product code | Qty. | Shape | Dimensions | |
|-----------------|------|---------------------|--------------------------------------|--|
| 5950030G | 1/cs | Small oval | 3.1" x 4.7" (8.0 cm x 12.0 cm) | |
| 5950040G | 1/cs | Medium oval | 4.3" x 5.5" (11.0 cm x 14.0 cm) | |
| 5950050G | 1/cs | Large oval | 5.4" x 7.0" (13.8 cm x 17.8 cm) | |
| 5950010G | 1/cs | Small circle | 3.0" (7.6 cm) diameter | |
| 5950020G | 1/cs | Large circle | 4.5" (11.4 cm) diameter | |
| 5950070G | 1/cs | Extra large oval | 7.7" x 9.7" (19.6 cm x 24.6 cm) | |
| 5950080G | 1/cs | Extra large oval | 8.7" x 10.7" (22.1 cm x 27.1 cm) | |
| 5950090G | 1/cs | Extra large oval | 10.8" x 13.7" (27.4 cm x 34.9 cm) | |
| 5950060G | 1/cs | Midline | 6.1" x 10.1" (15.5 cm x 25.7 cm) | |



CapSure**Permanent Fixation System
Indications. The CapSure **Permanent Fixation System is indicated for the approximation of soft tissue and fixation of surgical mesh to tissues during laparoscopic surgical procedures in ventral and inguinal hernia repair. Contraindications.1. This device is not intended for use except as indicated. 2. Do not use this device where hemostasis cannot be verified visually ofter application.3. Contraindications associated with laparoscopic surgical procedures relative to mesh fixation apply, including but not limited to: fixation of vascular or neural structures and in ischemic or necrotic tissue. 4. Carefully inspect the urea in the vicinity of the tissue being fastened to avoid inadvertent penetration of underlying structures such as bone, nerves, vessels, and viscera. Use of the CapSure** Permanent Fixation System in the close vicinity of such underlying structures is contraindicated. For reference, the length of the fastener below the fastener head is another 1 mm (total 4.2 mm). 5. This device should not be used in tissues that have a direct anotheris in the diaphragm in the vicinity of the pericardium, aorta, or inferior vena cava during diaphragmatic hernia repair. Warnings.1. The CapSure** Permanent Fixation System is intended for Single Use Only - DO NOT RESTERIUIZE. Reuse, reprocessing, resterilization or repackaging may og compromise the structural integrity and/or essential material and design characteristics that are critical to the overall performance of the device and may lead to device failure which may result in injury to the patient. Reuse, reprocessing, resterilization or repackaging may also create a risk of contamination of the device and/or cause patient inferition, including, but not limited to, the transmission of infectious diseases from one patient to another. Contamination of the device may lead to injury, illness or death of the patient or end user. 2. Do not use beyond the expiration date on the package, 3. This prort to using them together in a proced may damage the tissue, the material being fixated, and/or the device. //. If the device locks and cannot be separated from a fastener that has been deployed into mesh and/or tissue, rotate the device counterclockwise to free the fastener from the tissue and/or to free the device. If the fastener does not deploy properly, remove the device from the patient and test the device in gauze to ensure proper fastener deployment, otherwise discard the device appropriately and use a new CapSure™ Permanent Fixation System. Once proper fastener deployment is confirmed, the device may be reinserted into the patient. 8. The safety and effectiveness of CapSure™ Permanent Fixation System have not been evaluated or established in pregnant or breast feeding women. 9. This device contains the following substance(s) defined as CMR 1B in a concentration above 0.1% weight by weight: Cobalt; CAS No. 7440-48-4; EC No. 231-158-0. Current scientific evidence supports that medical devices manufactured from stainless-steel alloys containing cobalt do not cause an increased risk of cancer or adverse reproductive effects. For more information, please consult the ECHA website: https://echa.europa.eu/home Adverse Reactions. Adverse reactions and potential complications associated with fixation devices such as the CapSure™ Permanent Fixation System may include, but are not limited to the following: hemorrhage, pain, edema and erythema at wound site; septicemia/infection; hernia recurrence/ wound dehiscence, erosion and allergic response in patients with known sensitivities to PEEK and metals contained in 316L stainless steel, including chromium, nickel, copper, and iron.

OptiFix** Absorbable Fixation System
Indications. The OptiFix** Absorbable Fixation System is indicated for the approximation of soft tissue and fixation of surgical mesh to tissues during open or laparoscopic surgical procedures, such as hemia repair. Contraindications. 1.This device is not intended for use except as indicated. 2. Do not use this device where hemostasis cannot be verified visually after application. 3.

Contraindications associated with laparoscopic and open surgical procedures relative to mesh fixation apply, including but not ultimated to: • Fixation of vascular or neural structures • Fixation of oboration and cartilage • Situations with insufficient ingrowth of tissue into the mesh over time, which could result in inadequate fixation once the fasterier is absorbed. 4. Carefully inspect the area in the vicinity of the tissue being fastened to avoid inadvertent penetration of underlying structures such as nerves, vessels, viscera or bone. Use of the OptiFix** Absorbable Fixation System in the dose vicinity of such underlying structures is contraindicated. For reference, the length of the fastener below the fastener head is and mm, the fastener head is and in the vicinity of the period princip structures is contraindicated. For reference, the length of the fastener below the fastener head is and mm, the fastener head is an intended for Single Use (1,7) and in the vicinity of the period princip structures is contrained in the vicinity of the period princip structures in the vicinity of the vicinity of the period of the device and vicinity of the v and a new device should be used. 9. If the fastener does not deploy properly, remove the device from the patient and test the device in gauze to ensure proper fastener deployment. Once proper fastener deployment is confirmed, the device may be reinserted into the patient. Adverse Reactions. Adverse reactions and potential complications associated with fixation devices such as the OptiFix™ Absorbable Fixation System may include, but are not limited to the following: hemorrhage; pain, edema and erythema at wound site; allergic reaction to Poly(D, L)-lactide; infection/septicemia; hernia recurrence/wound dehiscence.

Ventrol[™] ST Hemia Patch
Indications. The Ventrol[™] ST Hernia Patch is indicated for use in the reinforcement of soft tissue, where weakness exists, in procedures involving soft tissue repair of ventral, incisional, and umbilical hernias. Contraindications. 1. Do not use this mesh in infants, children, or pregnant women, whereby future growth may be compromised by the use of such mesh materials. 2. The use of this mesh has not been studied in breastfeeding or pregnant women. 3. Do not use this mesh for the reconstruction of cardiovascular defects. 4. Literature reports that there may be a possibility for adhesion formation when the polypropylene is placed in contact with the bowel or screa. Warnings 1. The use of any permanent mesh or patch in a contaminated or infected wound could lead to fistula formation and/or extrusion of the mesh. 2. If an infection develops, treat the infection aggressively. Consideration should be given regarding the need to remove the mesh. An unresolved infection may require the removal of the mesh. 3. If the unused mesh has been in contact with instruments or supplies used on a patient or contaminated with bodily fluids, discard with care to prevent risk of transmission of viral infections. 4. To prevent recurrences when repairing hernias, the mesh should be sized with appropriate overlap for the size and location of the defect, taking into consideration any additional clinical factors applicable to the patient. Careful attention to mesh fixuation placement and spacing will help prevent excessive tension or gap formation between the mesh and fascial tissue. 5. This mesh is supplied sterile. Inspect the packaging to be sure it is intact and undranged prior to use. 6. This mesh has been designed for single use only. Reuse, resterilization, reprocessing and/or repackaging may compromise the structral integrity and/or essential material and design characteristics that are critical to the overall performance of the mesh and may lead to mesh failure which may result in injury to the pati

1 Preclinical data on file at BD. Results may not correlate to performance in humans. 2 Iannitti, D. et al. Technique and outcomes of abdominal incisional hernia repair using a synthetic composite mesh: a report of 455 cases. Journal of the American College of Surgeons. 2008 Jan; 206(1):83-8. 3 Please see the "Patch Technique" section in the Instructions for Use 4 Images are from a porcine study using the Ventrio™ ST Hernia Patch. Data on file. 5 Majercik, S. et al. Strength of tissue attachment to mesh after ventral hernia repair with synthetic composite mesh in a porcine model. Surg Endosc. 2006 Nov;20(11):1671-4. 6 Results may not correlate to performance in humans. 7 Preclinical results may not correlate to performance in humans. 8 Dr. Matthews is a paid consultant for BD. Financial support for the study was supplied by Atrium Medical Corporation.

Not all products, services, claims or features of products and services may be available or valid in your local area. Please check with your local BD Representative.

Disclaimer: Please consult product labels and instruction for use for indications, contraindications, hazards, warnings, and precautions

BD Switzerland Sarl

Terre Bonne Park – A4, Route De Crassier, 17, 1262 Eysins, Vaud, Switzerland T: + 41 21 556 3000

2797

